Medidata Reports Record First Quarter 2014 Results

  • Record revenues of $76.6 million, a 21% year-over-year increase
  • Record subscription revenue of $63.8 million, a 26% year-over-year increase
  • Record billings of $90 million, a 43% year-over-year increase
NEW YORK--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced its financial results for the first quarter of 2014.

"Interest in Medidata's platform is at an all-time high as our clients and prospects look to transform clinical development," said Tarek Sherif, Medidata's chairman and chief executive officer. "We are seeing great sales momentum, as our pipeline continues to build, giving us confidence that 2014 will be another outstanding year. Our industry focus, along with our ability to execute, innovate and make targeted strategic investments, is driving competitive advantage while laying the foundation for sustainable long-term success. Deep client relationships, client wins and strengthening partnerships with CROs and systems integrators are solidifying our leadership position in the global clinical research ecosystem."

First Quarter 2014 Results

  • Total revenues for the first quarter of 2014 were $76.6 million, an increase of $13.3 million, or 21%, compared with $63.3 million in 2013. Subscription revenue was $63.8 million, an increase of 26% compared with the same period last year.
  • GAAP operating income for the quarter was $0.3 million, compared with $7.1 million in the first quarter of 2013. Non-GAAP operating income* for the first quarter of 2014 was $12.5 million, compared with $14.2 million a year ago.
  • GAAP net (loss) for the first quarter of 2014 was ($1.8) million, or ($0.03) per diluted share, compared with net income of $5.7 million, or $0.11 per diluted share, in the first quarter of 2013. Adjusted non-GAAP net income* for the first quarter of 2014 was $5.9 million, or $0.11 per diluted share, compared with $9.1 million, or $0.17 per diluted share, in the first quarter of 2013. See the non-GAAP reconciliation included in this release for full details of the non-GAAP adjustments.
  • Total cash, cash equivalents and marketable securities were $403.5 million at the end of the first quarter of 2014, an increase of $279.5 million, or 225%, compared with $124.0 million at the end of the first quarter of 2013, primarily due to net proceeds from the convertible senior notes issued during 2013 and strong cash flows over the past year.
  • Cash flow from operations was ($6.3) million in the first quarter of 2014, compared with $2.9 million a year ago.

Additional Highlights

  • Medidata's customer base grew to 420, with 32 new clients added in the first quarter of 2014, an increase of 88% over the number of new clients added in the first quarter of 2013. Customer growth was realized in all regions and across multiple products.
  • 52% of customers had committed to multiple products at the end of the first quarter of 2014, up from 41% at the end of the first quarter of 2013.
  • Medidata's industry-leading CRO program continued to grow, with three new partners added, including a top 5 CRO. Several partners also began using a broader set of applications within the Medidata Clinical Cloud™, including Medidata's trial management solution for their own work.
  • Billings were $90 million in the first quarter of 2014, a 43% increase over the first quarter of 2013.
  • Subscription backlog for the remainder of the year as of March 31, 2014 increased to $177 million, an increase of $21 million year over year. Subscription backlog does not include revenues associated with intra-year renewals. Including a minimum of $15 million of revenue associated with remaining intra-year renewals, subscription backlog would have increased to $192 million.
  • Medidata's overall revenue retention rate was nearly 100%.

"We are off to a good start to the year and on track to achieving the financial outlook we provided earlier in the year," said Cory Douglas, Medidata's chief financial officer. "We continue to make disciplined investments to maximize our long-term opportunity to drive platform adoption while advancing our growth trajectory."

Conference Call

The company plans to host its investor conference call today at 8:00 a.m. Eastern. The investor conference call will be available via live webcast on the "Investor" section of Medidata's web site at http://investor.mdsol.com. To participate by telephone, domestic participants may dial 877-303-2528 and international participants may dial 847-829-0023. Those interested in participating in the conference call should dial in at least 10 minutes prior to the call to register. Participants can also join the call via a simultaneous live audio webcast, which will be made available on the "Investor" section of Medidata's web site at http://investor.mdsol.com. A replay of the conference call can be accessed until Tuesday, May 6, 2014, by dialing 800-585-8367 domestically or 404-537-3406 internationally, with the passcode 25420290. An archive of the call will also be hosted on the "Investor" section of Medidata's web site, http://investor.mdsol.com, for a limited period of time.

About Medidata

Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud™ brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

Cautionary Statement

Certain statements made in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Medidata Solutions, Inc. ("Medidata"), including but not limited to statements about Medidata's forecast of financial performance, products and services, business model, strategy and growth opportunities, and competitive position. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. In particular, the risks and uncertainties include, among other things, risks associated with possible fluctuations in our financial and operating results; errors, interruptions or delays in our service or our Web hosting; the financial impact of any future acquisitions; our ability to continue to release, and gain customer acceptance of, new and improved versions of our products; changes in our sales and implementation cycles; competition; our ability to retain and expand our customer base or increase new business from those customers; our ability to hire, retain and motivate our employees and manage our growth; regulatory developments; litigation; and general developments in the economy. For additional disclosure regarding these and other risks faced by the company, see disclosures contained in Medidata's public filings with the Securities and Exchange Commission including, the "Risk Factors" section of Medidata's Annual Report on Form 10-K for the year ended December 31, 2013. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof, and Medidata undertakes no obligation to update such statements as a result of new information.

*Non-GAAP Financial Information

Medidata provides non-GAAP operating income, net income and net income per share applicable to common stockholders data as additional information for its operating results. These measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. Non-GAAP operating income excludes the impact of depreciation, amortization of intangible assets associated with acquisitions, stock-based compensation expense, and an adjustment to the fair value of contingent consideration. Adjusted non-GAAP net income excludes the impact of tax-affected amortization of intangible assets associated with acquisitions, stock-based compensation expense, an adjustment to the fair value of contingent consideration, and non-cash interest expense on convertible senior notes. Management uses these non-GAAP measures to evaluate its financial results, develop budgets, manage expenditures, and as an important factor in determining variable compensation. In addition, investors frequently have requested information from management regarding depreciation, amortization and other non-cash charges, such as share-based compensation, and management believes, based on discussions with investors, that these non-GAAP measures enhance investors' ability to assess Medidata's historical and projected future financial performance. While management believes these non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of non-GAAP financial measures. One limitation of non-GAAP operating income is that it excludes depreciation and amortization, which represents the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in our business. Medidata compensates for these limitations by using these non-GAAP financial measures as supplements to GAAP financial measures and by reviewing the reconciliations of the non-GAAP financial measures to their most comparable GAAP financial measures. Investors are encouraged to review the reconciliations of these non-GAAP financial measures to the comparable GAAP results, which are attached to this press release.

 
MEDIDATA SOLUTIONS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
(Amounts in thousands, except per share data)
   

Three Months Ended
March 31,

    2014   2013
Revenues        
Subscription   $ 63,811     $ 50,652  
Professional services   12,829     12,607  
Total revenues   76,640     63,259  
Cost of revenues (1)(2)        
Subscription   11,086     9,025  
Professional services   9,713     8,104  
Total cost of revenues   20,799     17,129  
Gross profit   55,841     46,130  
Operating costs and expenses:        
Research and development (1)   17,789     11,905  
Sales and marketing (1)(2)   20,732     14,489  
General and administrative (1)   17,046     12,644  
Total operating costs and expenses   55,567     39,038  
Operating income   274     7,092  
Interest and other income (expense):        
Interest expense   (3,781 )   (18 )
Interest income   395     76  
Other income, net   34     154  
Total interest and other (expense) income, net   (3,352 )   212  
(Loss) income before income taxes   (3,078 )   7,304  
Provision for income taxes   (1,263 )   1,604  
Net (loss) income   $ (1,815 )   $ 5,700  
(Loss) earnings per share:        
Basic (3)   $ (0.03 )   $ 0.11  
Diluted (3)   $ (0.03 )   $ 0.11  
Weighted average common shares outstanding:        
Basic (3)   52,109     50,240  
Diluted (3)   52,109     52,522  

(1) Stock-based compensation expense included in cost of revenues and operating costs and
expenses is as follows:

       
Cost of revenues   $ 1,072     $ 487  
Research and development   912     458  
Sales and marketing   2,351     1,222  
General and administrative   5,364     3,038  
Total stock-based compensation   $ 9,699     $ 5,205  

(2) Amortization expense of intangible assets included in costs of revenues and operating costs
and expenses is as follows:

       
Cost of revenues   $ 108     $ 281  
Sales and marketing   30     113  
Total amortization of intangible assets   $ 138     $ 394  

(3) Prior period results have been adjusted to reflect the two-for-one stock split which was effected in the form of a stock
dividend in December 2013.

 

 

 
MEDIDATA SOLUTIONS, INC.

Reconciliation of GAAP Operating Income and GAAP Net (Loss) Income to
Non-GAAP Operating Income and Adjusted Non-GAAP Net Income (Unaudited)

(Amounts in thousands, except per share data)
   

Three Months Ended
March 31,

    2014   2013
Operating income:        
GAAP operating income   $ 274     $ 7,092  
GAAP operating margins   0.4 %   11.2 %
Stock-based compensation   9,699     5,205  
Depreciation and amortization   2,535     1,851  
Contingent consideration adjustment (1)       60  
Non-GAAP operating income   $ 12,508     $ 14,208  
Non-GAAP operating margins   16.3 %   22.5 %
Net income:        
GAAP net (loss) income   $ (1,815 )   $ 5,700  
Stock-based compensation   9,699     5,205  
Amortization   138     394  
Contingent consideration adjustment (1)       60  
Non-cash interest expense on convertible senior notes (2)   3,060      
Tax impact on add-back items (3)   (5,159 )   (2,264 )
Adjusted non-GAAP net income   $ 5,923     $ 9,095  
GAAP basic (loss) earnings per share (4)   $ (0.03 )   $ 0.11  
GAAP diluted (loss) earnings per share (4)   $ (0.03 )   $ 0.11  
Adjusted Non-GAAP basic earnings per share (4)   $ 0.11     $ 0.18  
Adjusted Non-GAAP diluted earnings per share (4)(5)   $ 0.11     $ 0.17  
                 
 
(1) Amount represents the effect of changes in fair value of contingent consideration liability.
(2) During the third quarter of 2013, we issued $287.5 million in convertible senior notes (the "Notes") with a coupon interest rate of 1.00%. Interest is paid semiannually on February 1 and August 1 over the five-year term of the notes. In connection with the Notes, we are required to recognize non-cash interest expense, including amortization of debt discount and issuance costs, in accordance with accounting guidance for convertible debt that may be settled in cash. We exclude this incremental non-cash interest expense for purposes of calculating adjusted non-GAAP net income. We believe that excluding these expenses from our non-GAAP measures is useful to investors because such incremental non-cash interest expense does not generate a cash outflow for the company and the debt issuance costs do not represent a cash outflow for the company except in the period the Notes were issued; therefore both are not indicative of our continuing operations or meaningful when comparing current results to past results.
(3) Tax impact calculated using a 40% tax rate.
(4) Prior period results have been adjusted to reflect the two-for-one stock split which was effected in the form of a stock dividend in December 2013.
(5) Adjusted non-GAAP diluted earnings per share for the three months ended March 31, 2014 is calculated using non-GAAP diluted weighted average dilutive common shares outstanding, which includes the effect of 3.2 million dilutive potential common shares.
 
The table above presents a reconciliation of GAAP to non-GAAP operating income, net income, and net income per share applicable to common stockholders for the three months ended March 31, 2014 and 2013. Non-GAAP operating income excludes the impact of depreciation, amortization of intangible assets associated with acquisitions, stock-based compensation expense, and adjustment to the fair value of contingent consideration. Adjusted non-GAAP net income excludes the impact of tax affected amortization of intangible assets associated with acquisitions, stock-based compensation expense, adjustment to the fair value of contingent consideration, and non-cash interest expense on convertible senior notes.
 

 

 
MEDIDATA SOLUTIONS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
(Amounts in thousands, except per share data)
    March 31, 2014   December 31, 2013
ASSETS        
Current assets:        
Cash and cash equivalents   $ 25,406     $ 22,328  
Marketable securities   196,140     218,892  

Accounts receivable, net of allowance for doubtful accounts of $1,089 and $1,055,
respectively

  66,326     45,534  
Prepaid commission expense   4,116     3,615  
Prepaid expenses and other current assets   12,434     13,511  
Deferred income taxes   2,310     665  
Total current assets   306,732     304,545  
Restricted cash   5,118     5,118  
Furniture, fixtures and equipment, net   40,482     41,229  
Marketable securities, long-term   181,947     195,105  
Goodwill   15,533     15,487  
Intangible assets, net   774     904  
Deferred income taxes, long-term   348     345  
Other assets   9,804     10,620  
Total assets   $ 560,738     $ 573,353  
LIABILITIES AND STOCKHOLDERS' EQUITY        
Current liabilities:        
Accounts payable   $ 5,812     $ 7,524  
Accrued payroll and other compensation   9,862     27,773  
Accrued expenses and other   8,978     12,265  
Deferred revenue   57,446     52,628  
Total current liabilities   82,098     100,190  
Noncurrent liabilities:        
Convertible 1.00% senior notes, net   232,446     229,705  
Deferred revenue, less current portion   3,255     1,430  
Deferred tax liabilities   5,654     5,651  
Other long-term liabilities   12,085     10,564  
Total noncurrent liabilities   253,440     247,350  
Total liabilities   335,538     347,540  
Commitments and contingencies        
Stockholders' equity:        

Preferred stock, par value $0.01 per share; 5,000 shares authorized, none issued and
outstanding

       

Common stock, par value $0.01 per share; 100,000 shares authorized, 55,640 and
55,018 shares issued; 54,078 and 53,634 shares outstanding, respectively

  556     550  
Additional paid-in capital   259,179     248,336  
Treasury stock, 1,562 and 1,384 shares, respectively   (36,244 )   (26,414 )
Accumulated other comprehensive loss   (16 )   (199 )
Retained earnings   1,725     3,540  
Total stockholders' equity   225,200     225,813  
Total liabilities and stockholders' equity   $ 560,738     $ 573,353  
                 

 

 
MEDIDATA SOLUTIONS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
(Amounts in thousands)
    Three Months Ended March 31,
    2014   2013
Cash flows from operating activities:        
Net (loss) income   $ (1,815 )   $ 5,700  

Adjustments to reconcile net (loss) income to net cash provided by operating
activities:

       
Depreciation and amortization   2,535     1,851  
Stock-based compensation   9,699     5,205  
Amortization of discounts or premiums on marketable securities   1,431     504  
Deferred income taxes   (1,643 )   718  
Amortization of debt issuance costs   319     15  
Amortization of debt discount   2,741      
Excess tax benefit associated with equity awards   (71 )   (610 )
Contingent consideration adjustment       60  
Provision for doubtful accounts   100     657  
Changes in operating assets and liabilities:        
Accounts receivable   (25,550 )   (4,249 )
Prepaid commission expense   (499 )   (917 )
Prepaid expenses and other current assets   1,485     684  
Other assets   137     (73 )
Accounts payable   1,083     (1,558 )
Accrued payroll and other compensation   (9,260 )   (6,643 )
Accrued expenses and other   832     1,518  
Deferred revenue   10,653     (287 )
Other long-term liabilities   1,537     322  
Net cash (used in) provided by operating activities   (6,286 )   2,897  
Cash flows from investing activities:        
Purchase of furniture, fixtures and equipment   (7,048 )   (2,947 )
Purchase of available-for-sale marketable securities   (46,249 )   (27,416 )
Proceeds from sale of available-for-sale marketable securities   80,730     30,030  
Net increase in restricted cash       388  
Net cash provided by investing activities   27,433     55  
Cash flows from financing activities:        
Proceeds from exercise of stock options   1,079     1,655  
Proceeds from employee stock purchase plan   1,327      
Excess tax benefit associated with equity awards   71     610  
Payment of acquisition-related earn-out   (704 )   (380 )
Repayment of obligations under capital leases   (30 )   (14 )
Acquisition of treasury stock   (19,789 )   (126 )
Repayment of notes payable   (41 )   (38 )
Net cash (used in) provided by financing activities   (18,087 )   1,707  
Net increase in cash and cash equivalents   3,060     4,659  
Effect of exchange rate changes on cash and cash equivalents   18     (51 )
Cash and cash equivalents - Beginning of period   22,328     32,683  
Cash and cash equivalents - End of period   $ 25,406     $ 37,291  
                 

 

Contacts

Medidata Solutions
Investor:
Hulus Alpay, 212-419-1025
[email protected]
or
Media:
Gail Janowitz, 212-918-1792
[email protected]

 

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.